Applied Genetic Technologies Corporation

152 articles with Applied Genetic Technologies Corporation

• Syncona Limited Portfolio Company Successfully Completes Tender Offer and Acquisition of Applied Genetic Technologies Corporation

  12/1/2022

  Applied Genetic Technologies Corporation, announced the successful completion of the previously announced tender offer to purchase all of the issued and outstanding shares of common stock of AGTC by a portfolio company of Syncona Limited .

• Syncona Limited Portfolio Company Extends Tender Offer to Acquire Applied Genetic Technologies Corporation

  11/29/2022

  Applied Genetic Technologies Corporation, announced that a portfolio company of Syncona Limited has extended the expiration of its previously announced tender offer to purchase all of the issued and outstanding shares of AGTC common stock for $0.34 per share in cash at closing, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.

• *REMINDER* AGTC Urges Shareholders to Tender Their Shares by November 28, 2022 *REMINDER*

  11/22/2022

  Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, reminds AGTC stockholders:

• Applied Genetic Technologies Corporation Urges Shareholders to Tender Their Shares by November 28, 2022

  11/14/2022

  Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, sent the following letter to stockholders.

• Applied Genetic Technologies Corporation Reminds Shareholders to Tender Their Shares by November 28, 2022

  11/3/2022

  Applied Genetic Technologies Corporation, President and Chief Executive Officer, Sue Washer, sent the following letter to shareholders:

• Syncona Commences Tender Offer for All Outstanding Shares of Applied Genetic Technologies Corporation

  10/26/2022

  Applied Genetic Technologies Corporation and a newly established portfolio company of Syncona Limited, announced the commencement of the previously announced tender offer for all of the issued and outstanding shares of common stock of AGTC at a price of $0.34 per share in cash, at the closing of the transaction, plus up to an additional $0.73 per share payable pursuant to contingent value rights upon the achievement of specified milestones.

• Syncona to Acquire Applied Genetic Technologies Corporation

  10/24/2022

  AGTC announced that it has entered into a definitive agreement pursuant to which a newly established portfolio company of Syncona Limited, will acquire AGTC, through a tender offer, for approximately $23.5 million in cash at the closing of the transaction plus potential future aggregate cash payments of up to $50.0 million pursuant to contingent value rights.

• AGTC to Participate in Upcoming September 2022 Investor Conferences

  9/1/2022

  Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.

• AGTC to Participate in Upcoming Investor Conferences - Aug 01, 2022

  8/1/2022

  Applied Genetic Technologies Corporation announced that management will be participating in the following investor conferences.

• AGTC Receives Positive Type C Meeting Feedback from the FDA for the Company’s Design and Operating Procedures of its Planned cGMP Manufacturing Facility

  7/26/2022

  Applied Genetic Technologies Corporation announced that the U.S. Food and Drug Administration provided favorable feedback on the Current Good Manufacturing Practice design of AGTC’s manufacturing facility.

• AGTC to Present at Upcoming American Society of Retina Specialists Annual MeetingJuly 7, 2022 at 8:00 AM EDT

  7/7/2022

  Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced two encore presentations on the interim safety results in three studies.

• AGTC Announces Key Appointments to Leadership Team

  6/8/2022

  Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the appointments of Eduardo Jacobo, P.E., as Senior Vice President of GMP Manufacturing, and Dr. David Jacobs, MD, MBA, FACP.

• AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting

  6/6/2022

  Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa (XLRP), at the 45th Macula Society Annual Meeting.

• AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

  6/1/2022

  Applied Genetic Technologies Corporation announced the formation of a scientific advisory board comprised of leading experts in age-related macular degeneration.

• AGTC to Present at the H.C. Wainwright Global Investment Conference

  5/18/2022

  Applied Genetic Technologies Corporation announced that Sue Washer, President & Chief Executive Officer, Jon Lieber, Chief Financial Officer, and Susan Schneider, Chief Medical Officer, will be presenting virtually at the H.C. Wainwright Global Investment Conference held May 23 - 26, 2022.

• AGTC Announces Positive Three-Month Interim Results from Skyline Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa

  5/16/2022

  Applied Genetic Technologies Corporation reported positive three-month interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based gene therapy targeting mutations in the RPGR gene in patients with X-linked retinitis pigmentosa.

• Positive 18-Month Data from Ongoing Phase 1/2 Clinical Study of AGTC-501 Presented at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

  5/4/2022

  Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the presentation of additional positive findings from the ongoing X-linked retinitis pigmentosa (XLRP) Phase 1/2 study of AGTC-501.

• AGTC to Present Preclinical Research Supporting Gene Therapy Platform in Frontotemporal Dementia at the 25th Annual Meeting of the American Society of Gene & Cell Therapy

  5/2/2022

  Applied Genetic Technologies Corporation (Nasdaq: AGTC), today announced preclinical data presented at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) that expands the potential utility of its gene therapy platform to address neurogenerative diseases, such as frontotemporal dementia, and to demonstrate robust gene expression using hybrid dual AAV vectors.

• AGTC to Present at Cell & Gene Meeting on the Mediterranean

  4/14/2022

  Applied Genetic Technologies Corporation today announced that Sue Washer, President & Chief Executive Officer, will present at the Alliance for Regenerative Medicine Cell & Gene Meeting on the Mediterranean in Barcelona, Spain on Thursday, April 21 at 9:30 PM CEST / 3:30 PM ET.

• AGTC to Showcase Interim Findings from Ongoing XLRP and Achromatopsia Phase 1/2 Trials at the Association for Research in Vision and Ophthalmology 2022 Annual Meeting

  4/4/2022

  Applied Genetic Technologies Corporation today announced multiple presentations related to the Company’s ongoing clinical trials in X-linked retinitis pigmentosa (XLRP) and chromatopsia (ACHM) at the Association for Research in Vision and Ophthalmology’s 2022 Annual Meeting (ARVO 2022), taking place May 1 – 4, 2022 in Denver, Colorado.